NeoALTTO: European Journal of Cancer (EJC)

Title of Publication

Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer

AUTHORS

Paolo Nuciforo; John Townend; Martine J. Piccart; Shona Fielding; Panagiota Gkolfi, Sarra El-Abed; Evandro de Azambuja; Gustavo Werutsky; Judith Bliss; Volker Moebus; Marco Colleoni; Alvaro Moerno Aspitia; Henry Gomez; Andrea Gombos; Maria A. Coccia-Portugal; Ling-Ming Tseng; Georg Kunz; Guillermo Lerzo; Joohyuk Sohn; Vladimir Semiglazov; Cristina Saura; Judith Kroep; Antonella Ferro; David Cameron; Richard Gelber; Jens Huober; Serena Di Cosimo

Publication Reference

European Journal of Cancer (EJC) | Volume 181 | Issue | Page(s) 92-101 | Publication Year 2023

ALEXANDRA | Journal of the American Medical Association (JAMA)

Feb 3, 2025

The addition of the immune therapy drug atezolizumab to chemotherapy after surgery did not provide benefit among patients with triple-negative breast cancer who are at high risk of recurrent disease.

ALTTO | ESMO Open

Oct 24, 2024

Final 10-year analysis of the ALTTO trial exploring dual anti-HER2 blockade with lapatinib + trastuzumab compared to trastuzumab alone.

APHINITY | Journal of Clinical Oncology

Sep 18, 2024

Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update

OlympiA results in the subset of patients from Japan

Apr 1, 2023

The consistency of results between the subset of patients from Japan and the global OlympiA population supports the clinical benefit of adjuvant olaparib for patients with gBRCA1/2pv and HER2-negative, high-risk eBC in Japan after completion of local treatment and neoadjuvant or adjuvant CT.

Cardiac Safety in the APHINITY trial

Jan 30, 2023

ESMO Open has published an article confirming the cardiac safety of adjuvant anti-HER2 treatment with pertuzumab and trastuzumab.

Overall survival in the OlympiA trial

Dec 1, 2022

OlympiA demonstrates statistically significant improvement in overall survival with adjuvant olaparib compared with placebo

APHINITY | Annals of Oncology

Sep 1, 2022

Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years’ follow-up

OlympiA | ESMO Virtual Plenary Abstract | Annals of Oncology

May 9, 2022

Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer

APHINITY | Journal of the National Cancer Institute (JNCI)

May 5, 2022

Impact of age on clinical outcomes and efficacy of adjuvant dual anti-HER2 targeted therapy

APHINITY | European Journal of Cancer (EJC)

Mar 18, 2022

Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial

FRONTIER SCIENCE | PUBLICATIONS